GO:1902153 regulation of response to DNA damage checkpoint signaling: Checkpoint Control Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902153 describes any process that modulates the frequency, rate or extent of response to DNA damage checkpoint signaling, placing it upstream of the core checkpoint effector machinery.
• The ATM-Chk2 and ATR-Chk1 kinase cascades are the principal signaling axes whose activity is tuned by regulators annotated to this term.
• Regulation occurs at multiple levels, including sensor recruitment, kinase activation, adaptor availability, phosphatase-mediated reversal, and miRNA-dependent fine-tuning.
• Loss or hyperactivation of checkpoint regulation causes genomic instability, radiosensitivity, chemoresistance, and immune-evasion phenotypes in cancer.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are the standard tools for causally testing regulators of this process.
• EDITGENE provides end-to-end CRISPR cell model generation and CRISPR library screening / bioinformatics services to dissect GO:1902153 regulators.
Description
GO:1902153, regulation of response to DNA damage checkpoint signaling, is a biological_process term that captures any process modulating the frequency, rate or extent of the cellular response to DNA damage checkpoint signal. DNA damage checkpoints are surveillance pathways that detect lesions and transiently halt cell-cycle progression to allow repair, and their output must be tightly regulated to avoid inappropriate arrest or unchecked proliferation. The term therefore sits one regulatory layer above the core checkpoint kinases and their substrates, encompassing activators, inhibitors, scaffolds, and feedback loops that set checkpoint sensitivity and duration. Understanding this regulatory layer is important because the strength and timing of checkpoint signaling determine whether a cell survives, senesces, or dies after genotoxic stress, with direct consequences for cancer therapy, radiation biology, and genome-editing safety. Researchers studying this term typically ask which proteins set the threshold for checkpoint activation, how post-translational modifications and non-coding RNAs tune the response, and how these regulators can be targeted or modeled experimentally.
regulation of response to DNA damage checkpoint signaling At A Glance
| GO ID | GO:1902153 |
|---|---|
| GO term | regulation of response to DNA damage checkpoint signaling |
| Ontology | biological_process |
| Synonym | regulation of DNA damage checkpoint effector process; regulation of response to signal involved in DNA damage checkpoint |
| Major function | Modulates the frequency, rate or extent of DNA damage checkpoint signaling output |
| Upstream regulators | ATM, ATR, DNA-PK, and their adaptor and sensor proteins |
| Downstream effectors | CHK1, CHK2, CDC25 phosphatases, p53, and cell-cycle machinery |
| Related processes | DNA repair, cell-cycle arrest, apoptosis, senescence, and immune signaling |
| Disease relevance | Cancer predisposition, radiosensitivity, chemoresistance, and genomic instability |
What Is GO:1902153?
In our own words, GO:1902153 encompasses any biological process that changes how strongly, how quickly, or how long a cell executes its DNA damage checkpoint signaling response. It does not describe the checkpoint kinases themselves, but rather the modulators that adjust the frequency, rate, or extent of that signaling, including upstream activators, downstream feedback inhibitors, and signal-dampening factors.
Why Is regulation of response to DNA damage checkpoint signaling Important in Cell Biology?
Regulation of response to DNA damage checkpoint signaling is important because the checkpoint is a double-edged sword: too little signaling permits propagation of damaged genomes, whereas too much or prolonged signaling drives therapy resistance and tissue toxicity. Because this GO term specifically covers the modulatory layer, it highlights druggable and editable nodes that can sensitize tumors to radiation or chemotherapy, protect normal tissues, or improve the precision of genome editing.
• Determines cell fate after ionizing radiation and genotoxic chemotherapy.
• Controls the balance between cell-cycle arrest, repair, senescence, and apoptosis.
• Modulates radiosensitivity and chemoresistance in solid tumors and leukemias.
• Influences immune recognition through DNA-damage-dependent PD-L1 regulation.
• Provides mechanistic biomarkers for precision oncology and DNA-repair-targeted therapies.
• Is conserved from yeast to plants to mammals, enabling cross-species mechanistic studies.
• Is fine-tuned by microRNAs and post-translational modifications.
• Represents a tractable target space for CRISPR screens and functional genomics.
What Happens During regulation of response to DNA damage checkpoint signaling?
Damage sensing and regulator recruitment
In simple terms: First, the cell must notice that DNA is broken and bring the right regulator proteins to the damage site.
The regulatory process begins when sensor complexes recognize DNA lesions and recruit upstream regulators such as ATM, ATR, and DNA-PK to damaged chromatin. Adaptor proteins including MDC1, 53BP1, and the MRN complex amplify the initial signal and set the threshold for checkpoint activation, thereby modulating the frequency and extent of downstream signaling. Because these recruitment steps are rate-limiting, they are prime targets for regulation annotated to GO:1902153.
Kinase cascade amplification and effector activation
In simple terms: The alarm signal is amplified through a kinase relay that switches on the checkpoint effector proteins.
Once recruited, ATM phosphorylates CHK2 while ATR phosphorylates CHK1, creating the two canonical checkpoint kinase axes that propagate the signal to CDC25 phosphatases, p53, and other effectors. Regulators annotated to GO:1902153 modulate the rate and extent of this cascade by controlling kinase autophosphorylation, adaptor availability, and substrate accessibility. The output is a coordinated cell-cycle arrest that provides time for repair.
Feedback inhibition and signal termination
In simple terms: After the damage is handled, the checkpoint must be switched off so the cell can resume division.
Sustained checkpoint signaling is toxic, so phosphatases such as WIP1 (PPM1D) and PP2A, as well as ubiquitin-dependent degradation of checkpoint proteins, reverse the signal. These negative regulators are themselves annotated to GO:1902153 because they modulate the extent and duration of checkpoint signaling. Failure of this termination step leads to persistent arrest or inappropriate recovery with damaged DNA.
Non-coding RNA and post-translational fine-tuning
In simple terms: Small RNAs and chemical modifications act like dimmer switches that adjust how loud the checkpoint signal is.
MicroRNAs such as miR-24, miR-125b, and miR-16 directly target checkpoint kinases and their regulators, adding a layer of post-transcriptional control to the response. Phosphorylation, acetylation, ubiquitination, and SUMOylation of checkpoint components further tune the amplitude and kinetics of signaling. These mechanisms collectively define the regulatory scope of GO:1902153.
Integration with repair, apoptosis, and immune signaling
In simple terms: The checkpoint does not act alone; it talks to repair, death, and immune pathways to decide the cell's fate.
Regulated checkpoint signaling interfaces with homologous recombination and non-homologous end joining to coordinate repair choice. When damage is irreparable, the same regulatory layer can shift the balance toward apoptosis or senescence. DNA-damage-dependent regulation of PD-L1 expression further links this process to tumor immune evasion and immunotherapy response.
Key Genes Involved in GO:1902153 regulation of response to DNA damage checkpoint signaling
The following genes and proteins represent core components and regulators whose activity is directly relevant to GO:1902153.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATM | Master kinase that initiates checkpoint signaling after double-strand breaks | Knockout and point-mutation models for ataxia-telangiectasia and radiosensitivity |
| ATR | Kinase that responds to replication stress and single-stranded DNA | Essential for replication-fork checkpoint regulation and chemoresistance studies |
| CHEK1 | Effector kinase downstream of ATR that enforces cell-cycle arrest | Target for checkpoint inhibitor studies and CRISPR KO in cancer lines |
| CHEK2 | Effector kinase downstream of ATM that amplifies the checkpoint signal | Germline variants linked to breast and prostate cancer risk |
| TP53 | Transcription factor that integrates checkpoint signaling with apoptosis and senescence | Most frequently mutated gene in human cancer; central to checkpoint regulation |
| MDC1 | Adaptor that recruits and retains checkpoint regulators at damage sites | Used to study signal amplification and threshold setting |
| H2AX | Histone variant phosphorylated at damage sites to anchor regulators | Readout of checkpoint activation in imaging and proteomics |
| TP53BP1 | Chromatin reader that influences repair pathway choice and checkpoint strength | Knockout models reveal its role in 53BP1-dependent regulation |
| CDC25A | Phosphatase inhibited by CHK1 to enforce cell-cycle arrest | Overexpression models test checkpoint bypass and chemoresistance |
| CDC25C | Phosphatase regulated by CHK1/CHK2 to control mitotic entry | Point-mutation models probe phosphorylation-dependent regulation |
| PPM1D | WIP1 phosphatase that terminates checkpoint signaling | Amplified in cancers; knockout models show prolonged checkpoint arrest |
| RAD51 | Recombinase whose regulation is coordinated with checkpoint signaling | Knock-in reporters track repair-checkpoint coupling |
| BRCA1 | Tumor suppressor that links checkpoint regulation to homologous recombination | CRISPR KO models for hereditary breast and ovarian cancer |
| MRE11 | Component of the MRN sensor complex that activates ATM | Point mutations cause ataxia-telangiectasia-like disorder |
| NBN | Nibrin, part of MRN complex, required for ATM recruitment | Knockout models for Nijmegen breakage syndrome |
| CDKN1A | p21, transcriptional target that enforces checkpoint arrest | Overexpression and KO models for cell-cycle regulation |
| AURKA | Mitotic kinase that modulates checkpoint recovery and mitotic entry | Used in studies of checkpoint adaptation and cancer therapy |
| PLK1 | Polo-like kinase that promotes checkpoint recovery and mitotic resumption | Inhibitor and CRISPR studies link it to radiosensitization |
How Is regulation of response to DNA damage checkpoint signaling Regulated?
The regulatory layer described by GO:1902153 is itself controlled by multiple inputs. Upstream, sensor complexes and chromatin marks determine how efficiently ATM and ATR are activated. Downstream, phosphatases such as WIP1 and PP2A, ubiquitin ligases, and microRNAs set the duration and amplitude of checkpoint signaling. In addition, cell-cycle phase, metabolic state, and environmental stresses such as osmotic or oxidative stress can modulate checkpoint responsiveness, as shown in plant and mammalian systems. This multilayered regulation ensures that checkpoint output is proportional to damage load and is reversible once repair is complete.
regulation of response to DNA damage checkpoint signaling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ATM | Ataxia-telangiectasia; radiosensitivity; breast cancer risk | CRISPR knockout in lymphoblastoid and epithelial cell lines |
| CHEK2 | Hereditary breast and prostate cancer predisposition | Point-mutation knock-in to model kinase-dead variants |
| TP53 | Li-Fraumeni syndrome; most sporadic cancers | Knockout and hotspot point-mutation isogenic pairs |
| PPM1D | Cancer amplification; chemoresistance | Overexpression and knockout models to test checkpoint duration |
| BRCA1 | Hereditary breast and ovarian cancer; PARP inhibitor response | Knock-in of patient-derived mutations and reporter assays |
Cancer and genomic instability
Dysregulation of DNA damage checkpoint signaling is a hallmark of cancer. Loss-of-function mutations in ATM, CHEK2, TP53, or BRCA1 impair checkpoint control and predispose to malignancies, whereas hyperactivation of the same pathways contributes to chemoresistance and radioresistance. Regulators annotated to GO:1902153 are therefore candidate biomarkers and therapeutic targets in precision oncology.
Neurodegeneration and premature aging
Defective checkpoint regulation leads to accumulation of DNA damage in post-mitotic neurons, contributing to neurodegeneration and premature aging phenotypes observed in ataxia-telangiectasia and related disorders. Because neurons cannot easily replace damaged cells, even subtle changes in checkpoint signaling can have profound consequences.
Immune evasion and immunotherapy response
DNA damage and checkpoint signaling regulate PD-L1 expression in cancer cells, linking this GO term to immune escape and response to immune checkpoint blockade. Modulating checkpoint regulators may therefore synergize with immunotherapy in tumors with high genomic instability.
Environmental stress and plant biology
Cell-cycle checkpoint control in response to DNA damage by environmental stresses is conserved in plants, where regulators of checkpoint signaling influence growth, development, and stress tolerance. This conservation makes plant models useful for dissecting core regulatory mechanisms that also operate in humans.
From regulation of response to DNA damage checkpoint signaling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate regulator required for checkpoint activation? | CRISPR knockout cell line with ionizing radiation and CHK1/CHK2 phosphorylation readouts |
| Does a specific phosphorylation site control checkpoint amplitude? | Point-mutation knock-in of phospho-dead or phospho-mimetic residues |
| How does a regulator affect checkpoint duration? | Endogenous tagged knock-in with live-cell imaging of checkpoint reporters |
| Does overexpression of a regulator drive chemoresistance? | Doxycycline-inducible overexpression cell model treated with genotoxins |
| Which regulators cooperate in a pathway? | CRISPR library screening with DNA-damage selection and bioinformatic hit calling |
| Can a regulator be targeted to radiosensitize tumors? | Isogenic knockout and wild-type pairs in cancer cell lines followed by clonogenic survival |
How to Study the regulation of response to DNA damage checkpoint signaling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-immunoblotting | Activation status of ATM, ATR, CHK1, CHK2, H2AX | Validation of checkpoint regulation after irradiation |
| Quantitative phospho-proteomics | Global changes in phosphorylation networks | Discovery of new regulatory nodes in GO:1902153 |
| Live-cell imaging | Kinetics of foci formation and checkpoint reporter activity | Single-cell analysis of signal duration and recovery |
| RNA-seq | Transcriptional output of checkpoint and repair genes | Pathway-level analysis of regulatory responses |
| Small RNA-seq | MicroRNA expression changes after DNA damage | Identification of miRNA-based checkpoint regulators |
| CRISPR knockout screen | Gene requirements for checkpoint-mediated survival | Genome-wide discovery of regulators |
| CRISPR activation screen | Gain-of-function effects on checkpoint signaling | Identification of suppressors and enhancers |
| Bioinformatic enrichment | Overlap of hits with GO:1902153 and DNA repair terms | Functional interpretation of screening data |
Phospho-proteomics and immunoblotting
Quantitative phospho-proteomics and targeted immunoblotting for ATM, ATR, CHK1, CHK2, and H2AX provide direct readouts of checkpoint signaling amplitude and kinetics after DNA damage. These methods are essential for validating whether a candidate regulator annotated to GO:1902153 changes the rate or extent of checkpoint activation.
Live-cell imaging of checkpoint reporters
Fluorescent reporters for DNA damage foci, cell-cycle phase, and checkpoint kinase activity enable real-time measurement of signaling dynamics in single cells. Tagged knock-in lines expressing fluorescently labeled checkpoint proteins allow tracking of recruitment and turnover at damage sites.
Transcriptomics and microRNA profiling
RNA-seq and small RNA-seq reveal transcriptional and microRNA-mediated changes in checkpoint regulators after genotoxic stress. These datasets help identify regulatory nodes that modulate the response to DNA damage checkpoint signaling.
CRISPR functional genomics and bioinformatics
Pooled CRISPR knockout and activation screens coupled with DNA-damage selection identify regulators that modify checkpoint sensitivity and cell survival. Downstream bioinformatics, including pathway enrichment and network analysis, maps hits onto GO:1902153 and related processes.
How CRISPR Can Be Used to Study GO:1902153 regulation of response to DNA damage checkpoint signaling
Knockout
CRISPR knockout of candidate regulators is the most direct way to test necessity for DNA damage checkpoint signaling. Isogenic knockout lines challenged with ionizing radiation or replication stress reveal whether loss of the gene changes CHK1/CHK2 phosphorylation, cell-cycle arrest, or survival. Such models are widely used to study ATM, ATR, CHEK1, CHEK2, and TP53 pathway components.
Point Mutation
Point-mutation knock-in allows precise interrogation of phosphorylation sites, catalytic residues, and disease-associated variants in checkpoint regulators. For example, phospho-dead or phospho-mimetic mutations in CDC25 or CHK2 can reveal how specific modifications tune checkpoint amplitude and duration. These models are critical for distinguishing correlation from causation in GO:1902153 research.
Knock-in
Tagged knock-in of endogenous checkpoint proteins with fluorescent or epitope tags enables live-cell imaging and proteomic analysis of regulator dynamics at physiological expression levels. Knock-in of reporter cassettes downstream of checkpoint-responsive promoters provides sensitive readouts of signaling activity.
Overexpression
Doxycycline-inducible or constitutive overexpression models test sufficiency of a candidate regulator to amplify or dampen checkpoint signaling. Overexpression of WIP1, for instance, shortens checkpoint duration and promotes chemoresistance, whereas overexpression of checkpoint kinases can enhance arrest. These models complement knockout studies to establish bidirectional causality.
How EDITGENE Supports regulation of response to DNA damage checkpoint signaling Research
Researchers studying regulation of response to DNA damage checkpoint signaling-related genes often need to determine whether a candidate gene is causally involved in setting checkpoint threshold, amplitude, or duration, and to translate that finding into disease-relevant models. EDITGENE provides the CRISPR cell model and screening infrastructure to move from correlation to causation with publication-grade rigor.
Contact EDITGENE today to design your custom CRISPR model for regulation of response to DNA damage checkpoint signaling research.
Frequently Asked Questions About regulation of response to DNA damage checkpoint signaling
What is GO:1902153 regulation of response to DNA damage checkpoint signaling?
GO:1902153 is a Gene Ontology biological_process term describing any process that modulates the frequency, rate or extent of response to DNA damage checkpoint signaling, encompassing activators, inhibitors, and feedback regulators of the checkpoint.
What genes are involved in regulation of response to DNA damage checkpoint signaling?
Key genes include ATM, ATR, CHEK1, CHEK2, TP53, MDC1, H2AX, TP53BP1, CDC25A, CDC25C, PPM1D, BRCA1, RAD51, MRE11, and NBN, all of which modulate checkpoint signaling.
Why is regulation of DNA damage checkpoint signaling important in cancer?
Altered checkpoint regulation causes genomic instability, radiosensitivity, chemoresistance, and immune evasion, making it central to cancer development and therapy response.
How do ATM and ATR regulate DNA damage checkpoint signaling?
ATM responds primarily to double-strand breaks and activates CHK2, while ATR responds to replication stress and single-stranded DNA and activates CHK1, together forming the core checkpoint kinase axes.
What is the role of microRNAs in DNA damage checkpoint regulation?
MicroRNAs such as miR-24 and miR-125b target checkpoint kinases and their regulators, providing post-transcriptional fine-tuning of the response to DNA damage.
How can CRISPR be used to study GO:1902153?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models allow causal testing of whether a candidate gene modulates checkpoint amplitude, duration, or cell survival after DNA damage.
What experimental models are used to study DNA damage checkpoint regulation?
Common models include isogenic cancer cell lines with CRISPR edits, phospho-immunoblotting, live-cell imaging reporters, RNA-seq, and pooled CRISPR screens with genotoxic selection.
What diseases are linked to defective DNA damage checkpoint regulation?
Defective regulation is linked to ataxia-telangiectasia, Li-Fraumeni syndrome, hereditary breast and ovarian cancer, Nijmegen breakage syndrome, neurodegeneration, and premature aging.
How does PPM1D regulate checkpoint signaling?
PPM1D (WIP1) is a phosphatase that dephosphorylates ATM, CHK1, and CHK2, thereby terminating checkpoint signaling and promoting recovery from DNA damage.
What methods measure DNA damage checkpoint activity?
Phospho-immunoblotting for ATM, ATR, CHK1, CHK2, and H2AX, quantitative phospho-proteomics, live-cell imaging, and clonogenic survival assays are standard methods.
Conclusion
GO:1902153 regulation of response to DNA damage checkpoint signaling defines the critical modulatory layer that sets the sensitivity, amplitude, and duration of the DNA damage checkpoint. Its components, from ATM and ATR to CHK1, CHK2, PPM1D, and microRNA regulators, determine cell fate after genotoxic stress and are deeply implicated in cancer, neurodegeneration, and therapy response. CRISPR-based knockout, point-mutation, knock-in, overexpression, and library screening approaches now make it possible to dissect this regulatory network with causal precision. EDITGENE offers the full suite of cell model and bioinformatics services to accelerate research on GO:1902153 and its disease connections.
References
- 1. Santivasi WL et al.. 2014. Ionizing radiation-induced DNA damage, response, and repair.. Antioxid Redox Signal 21(2):251-9 PMID: 24180216
- 2. Smith J et al.. 2010. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.. Adv Cancer Res 108:73-112 PMID: 21034966
- 3. Borgmann K et al.. 2016. DNA Repair.. Recent Results Cancer Res 198:1-24 PMID: 27318679
- 4. Wan G et al.. 2011. miRNA response to DNA damage.. Trends Biochem Sci 36(9):478-84 PMID: 21741842
- 5. Pedroza-Garcia JA et al.. 2022. Cell cycle checkpoint control in response to DNA damage by environmental stresses.. Plant J 109(3):490-507 PMID: 34741364
- 6. Lanz MC et al.. 2019. DNA damage kinase signaling: checkpoint and repair at 30 years.. EMBO J 38(18):e101801 PMID: 31393028
- 7. Sato H et al.. 2019. Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine.. Cancer Sci 110(11):3415-3423 PMID: 31513320
- 8. Li L et al.. 2005. Sensing, signaling, and responding to DNA damage: organization of the checkpoint pathways in mammalian cells.. J Cell Biochem 94(2):298-306 PMID: 15578575
